Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MPS cardioplegic formula
- Development stage
- Unknown
- Lead developer
- Quest Medical
- Modality
- Small Molecules
- Administration
- Intracoronary
01
Overview
MPS cardioplegic formula refers to a microplegia solution typically delivered using the Quest Medical Myocardial Protection System (MPS) during cardiac surgery. Unlike traditional large-volume crystalloid cardioplegia, this formula utilizes the patient's own autologous blood as the primary vehicle, which is precisely titrated with small volumes of concentrated additives including potassium chloride, magnesium sulfate, and lidocaine. The primary mechanism of action involves inducing rapid diastolic cardiac arrest through hyperkalemic depolarization of the myocardial cell membrane, while magnesium and lidocaine provide additional membrane stabilization and calcium antagonism to minimize ischemic injury. This approach is designed to reduce hemodilution, improve oxygen delivery to the myocardium during arrest, and allow for real-time adjustment of the cardioplegia composition based on the patient's physiological needs during cardiopulmonary bypass.
- Brand names
- Quest MPS
- Other names
- MicroplegiaBlood microplegiaQuest microplegiaMPS microplegia formula
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)Kir (Inward-rectifier potassium channels)SCN5A (Sodium channel protein type 5 subunit alpha)CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on MPS cardioplegic formula.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MPS cardioplegic formula.